Fibrinogen concentrate - Biotest AG

Drug Profile

Fibrinogen concentrate - Biotest AG

Alternative Names: BT-524

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Biotest AG
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Afibrinogenaemia

Most Recent Events

  • 01 Mar 2013 Phase-I/II clinical trials in Afibrinogenaemia in Italy (IV) (NCT02065882)
  • 31 Dec 2012 Preclinical trials in Afibrinogenaemia in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top